19 results on '"Dyrskjot L"'
Search Results
2. Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer
3. 1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial
4. A0358 - Reducing the number of flexible cystoscopies in patients undergoing follow-up for non-muscle invasive bladder cancer with either flexible cystoscopy or the urinary biomarker test bladder cancer monitor: A secondary outcome from a randomised clinical trial
5. A0236 - Two-year follow-up after dose-dense chemoresection with mitomycin C compared with adjuvant instillations for recurrent NMIBC − a randomised controlled trial
6. Molecular Correlates of Cisplatin-based Chemotherapy Response in Muscle Invasive Bladder Cancer by Integrated Multi-omics Analysis
7. STAG2 and PPARg as drivers of luminal-type bladder cancer
8. 86P - Longitudinal assessment of multiplex patient-specific ctDNA biomarkers in bladder cancer for diagnosis, surveillance and recurrence
9. 380 - Prognostic impact of a 12-gene progression score in non-muscle invasive bladder cancer: A prospective multicenter validation study
10. 837 Improved diagnostic urine assay to select patients for initial cystoscopy
11. 238 Urinary biomarkers in the follow-up of low grade non-muscle invasive bladder cancer patients: Update on the FP7 UROMOL project
12. 628 MICRORNAS ARE REPRODUCIBLY DEREGULATED IN PROSTATE CARCINOMA AND ARE POTENTIAL REGULATORS OF SIGNAL TRANSDUCTION PATHWAYS LIKE PI3-KINASE OR MAP-KINASE PATHWAYS
13. 158 URINARY BIOMARKERS FOR THE DETECTION OF NON- MUSCLE-INVASIVE BLADDER CANCER RECURRENCES: THE EUROPEAN UROMOL PROJECT
14. MP-16.10 Expression Profiling of Laser Micro Dissected Prostate Cancer Cells Delineates Genes Associated With Biochemical Recurrence After Radical Prostatectomy
15. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer
16. 139 Annexin A10 (ANXA10) is a marker for metastasis and disease progression in bladder cancer
17. 419 GENE EXPRESSION SIGNATURE FOR METASTATIC UROTHELIAL CARCINOMA OF THE URINARY BLADDER
18. PD-11.08: Bladder cancer outcome prediction using gene expression signatures–a large scale international validation study
19. A Molecular Signature in Superficial Bladder Carcinoma Predicts Clinical Outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.